Delta-like ligand 4 inhibitor drug treatment induces pulmonary hypertension in cancer clinical trials

8 November 2024

Casandra E. BesseNolan M. WinickiCristian PuertaMoises HernandezJason X.-J. YuanPatricia A. Thistlethwaite

https://doi.org/10.1002/pul2.12450

Abstract

Delta-like ligand 4 (DLL-4) inhibitor drugs are an emerging cancer treatment. In clinical trials for solid organ malignancies, intravenous administration of monoclonal antibodies that inhibit DLL-4 is associated with development of pulmonary hypertension, in the absence of left ventricular dysfunction. Analysis of 13 clinical trials showed that pulmonary hypertension is a complication of DLL-4 inhibition.

Read the full research letter

Share:
Additional comments are available to members. Login or register to become a member today